Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALENDULA: Cabotegravir/Lenacapavir in HIV-1
NCT06657885Phase 2Withdrawn
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenacapavir and cabotegravir in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoint: Percentage of participants with virological failure at 48 weeks. Planned start Jan 2025; status: withdrawn.
02
Drugs
lenacapavircabotegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06657885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657885.